Bacterially produced recombinant influenza vaccines based on virus-like particles

Although current influenza vaccines are effective in general, there is an urgent need for the development of new technologies to improve vaccine production timelines, capacities and immunogenicity. Herein, we describe the development of an influenza vaccine technology which enables recombinant produ...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2013-11, Vol.8 (11), p.e78947-e78947
Main Authors: Jegerlehner, Andrea, Zabel, Franziska, Langer, Alice, Dietmeier, Klaus, Jennings, Gary T, Saudan, Philippe, Bachmann, Martin F
Format: Article
Language:English
Subjects:
Animals
Antibodies, Viral - immunology
Antigenic determinants
Antisera
Bacteria
Biotechnology
Clinical trials
Dermatology
Development and progression
E coli
Epitopes
Hemagglutination
Hemagglutinin Glycoproteins, Influenza Virus - genetics
Hemagglutinin Glycoproteins, Influenza Virus - immunology
Hemagglutinins
Homology
Humans
Immune serum
Immunization
Immunogenicity
Immunoglobulins
Infections
Influenza
Influenza A Virus, H1N1 Subtype - genetics
Influenza A Virus, H1N1 Subtype - immunology
Influenza vaccines
Influenza Vaccines - biosynthesis
Influenza Vaccines - genetics
Influenza Vaccines - immunology
Innovations
Lectins
Mice
New technology
Pandemics
Proteins
Public health
Swine flu
Vaccination
Vaccine Potency
Vaccines
Virus-like particles
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although current influenza vaccines are effective in general, there is an urgent need for the development of new technologies to improve vaccine production timelines, capacities and immunogenicity. Herein, we describe the development of an influenza vaccine technology which enables recombinant production of highly efficient influenza vaccines in bacterial expression systems. The globular head domain of influenza hemagglutinin, comprising most of the protein's neutralizing epitopes, was expressed in E. coli and covalently conjugated to bacteriophage-derived virus-like particles produced independently in E.coli. Conjugate influenza vaccines produced this way were used to immunize mice and found to elicit immune sera with high antibody titers specific for the native influenza hemagglutinin protein and high hemagglutination-inhibition titers. Moreover vaccination with these vaccines induced full protection against lethal challenges with homologous and highly drifted influenza strains.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0078947